Published in Inflamm Bowel Dis on January 01, 2006
Concomitant Thyroid Disorders and Inflammatory Bowel Disease: A Literature Review. Biomed Res Int (2016) 0.77
Papillary thyroid cancer and ulcerative colitis. Gastroenterol Hepatol Bed Bench (2013) 0.76
Papillary thyroid cancer and inflammatory bowel disease: is there a relationship? World J Gastroenterol (2013) 0.76
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology (2003) 3.43
Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40
Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis (2010) 3.09
Ulcerative colitis. Lancet (2002) 2.10
Factors that affect adherence to surveillance colonoscopy in patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 2.06
Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care (2007) 2.04
Utility of CT in the emergency department in patients with ulcerative colitis. Inflamm Bowel Dis (2015) 1.98
Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol (2003) 1.88
Abdominal epilepsy. Best Pract Res Clin Gastroenterol (2005) 1.81
Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol (2012) 1.66
Focal physiologic fluorodeoxyglucose activity in the gastrointestinal tract is located within the colonic lumen. Nucl Med Commun (2012) 1.52
Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol (2011) 1.51
Management of acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol (2009) 1.42
Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.40
Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. J Clin Gastroenterol (2014) 1.39
Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges? Am J Gastroenterol (2002) 1.33
Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol (2003) 1.29
Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis (2013) 1.27
Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev (2009) 1.20
Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J (2011) 1.16
Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol (2006) 1.14
Melanin-concentrating hormone as a mediator of intestinal inflammation. Proc Natl Acad Sci U S A (2008) 1.12
Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes (2011) 1.10
Regular consumption of nuts is associated with a lower risk of cardiovascular disease in women with type 2 diabetes. J Nutr (2009) 1.08
Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol (2013) 1.08
Comment on Moshkovska et al. Inflamm Bowel Dis (2013) 1.07
In silico gene expression analysis--an overview. Mol Cancer (2007) 1.06
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother (2008) 1.05
Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut (2007) 1.05
Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2014) 1.02
Curcumin for clinical and endoscopic remission in ulcerative colitis. Inflamm Bowel Dis (2011) 1.02
The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf (2007) 1.01
Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis (2014) 1.01
The utility of capsule endoscopy in patients with suspected Crohn's disease. Am J Gastroenterol (2009) 0.97
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol (2010) 0.95
Capsule endoscopy for small-bowel evaluation in Crohn's disease. Gastrointest Endosc (2011) 0.94
Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology (2008) 0.94
Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. J Crohns Colitis (2009) 0.94
Inflammatory bowel disease. Medical therapy of specific clinical presentations. Gastroenterol Clin North Am (2002) 0.93
A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol (2013) 0.93
The role of adipokines in relation to HIV lipodystrophy. AIDS (2007) 0.93
Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis (2013) 0.92
The Role of Antibiotics in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2005) 0.92
Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2005) 0.91
Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs (2008) 0.91
Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis (2011) 0.90
Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs (2008) 0.90
Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. Cell Immunol (2013) 0.90
Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis (2012) 0.89
CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur J Immunol (2012) 0.89
Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease. Gastroenterol Clin North Am (2012) 0.88
Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. Inflamm Bowel Dis (2016) 0.87
Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis (2011) 0.87
Efficacy of IV Buscopan as a muscle relaxant in CT colonography. Eur Radiol (2003) 0.87
Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. Inflamm Bowel Dis (2014) 0.86
Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol (2012) 0.86
Effect of iron overload on glucose metabolism in patients with hereditary hemochromatosis. Metabolism (2009) 0.85
Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis (2004) 0.85
Colonic surveillance by CT colonography using axial images only. Eur Radiol (2004) 0.85
Documented compliance with inflammatory bowel disease quality measures is poor. Dig Dis Sci (2014) 0.84
Systematic analysis underlying the quality of the scientific evidence and conflicts of interest in gastroenterology practice guidelines. Am J Gastroenterol (2013) 0.84
Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci (2009) 0.83
Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. Cochrane Database Syst Rev (2014) 0.83
Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol (2011) 0.83
Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease. Curr Gastroenterol Rep (2015) 0.83
Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab (2003) 0.82
Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis (2011) 0.82
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol (2012) 0.82
The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. Inflamm Bowel Dis (2014) 0.82
Ulcerative colitis: current treatment strategies and future prospects. Therap Adv Gastroenterol (2009) 0.81
Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scans. Nucl Med Commun (2014) 0.81
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81
Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (2012) 0.81
Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.81
Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis (2010) 0.81
Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update. Clin Exp Gastroenterol (2009) 0.80
Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis (2011) 0.80
Efficacy and safety of drugs for ulcerative colitis. Expert Opin Drug Saf (2010) 0.80
In silico analysis of T-bet activity in peripheral blood mononuclear cells in patients with inflammatory bowel disease (IBD). In Silico Biol (2009) 0.79
Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs (2006) 0.79
The effects of caffeinated and decaffeinated coffee on sex hormone-binding globulin and endogenous sex hormone levels: a randomized controlled trial. Nutr J (2012) 0.78
Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 0.78
Adding fuel to the fire: GM-CSF for active Crohn's disease. Gastroenterology (2005) 0.78
Nephrolithiasis in patients with inflammatory bowel disease in the community. Int J Nephrol Renovasc Dis (2013) 0.78
Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. Inflamm Bowel Dis (2015) 0.78